Debbie Rigby rounds up the latest in research news
In this study analysis of individual patient data from randomised trials shows low doses of aspirin (75–100 mg) were only effective in preventing vascular events in patients weighing less than 70 kg, and had no benefit in the 80% of men and nearly 50% of all women weighing 70 kg or more. By contrast, higher doses of aspirin were only effective in patients weighing 70 kg or more. The authors suggest a one-dose-fits-all approach to aspirin is unlikely to be optimal, and a more tailored strategy is required.
Lancet, Published Online July 12, 2018
Data from the 2015 South Australian Health Omnibus Survey suggests self-report adherence to urate-lowering therapy (ULT) for the treatment of gout is low, with only 55% of respondents adhering to ULT. Predictors of ULT use included male gender, lower socioeconomic status, and concomitant cholesterol-lowering therapy. Respondents with gout with a higher BMI were more likely to remain on ULT.
Arthritis Research & Therapy 2018;20:143.
Date from nearly 200,000 UK patients taking warfarin, apixaban, rivaroxaban or dabigatran for 3-11 months suggests that apixaban is the safest drug, with reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin. Rivaroxaban and low dose apixaban were, however, associated with increased risks of all-cause mortality compared with warfarin.
This review article provides a summary of relevant data regarding the use of SGLT2i medicines and specific considerations for appropriate prescribing within the T2DM management pathway. People with T2DM can experience weight loss with SGLT2i agents, which encourages them to adhere to treatment. In addition, a useful benefit/risk tool is provided that summarises many of the aspects discussed in this review.
Diabetes Therapy, first online 23 July 2018.